Increasing SARS-CoV2 cases, hospitalizations and deaths among the vaccinated elderly populations during the Omicron (B.1.1.529) variant surge in UK

Venkata R. Emani; Vivek K. Pallipuram; Kartik K. Goswami; Kailash R. Maddula; Raghunath Reddy; Abirath S. Nakka; Sravya Panga; Nikhila K. Reddy; Nidhi K. Reddy; Dheeraj Nandanoor; Sanjeev Goswami

doi:10.1101/2022.06.28.22276926

ABSTRACT

BACKGROUND There were increased SARS-CoV2 hospitalizations and deaths noted during Omicron (B.1.1.529) variant surge in UK despite decreased cases, and the reasons are unclear.

METHODS In this retrospective observational study, we analyzed reported SARS-CoV2 cases, hospitalizations and deaths during the COVID-19 pandemic in the UK. We also analyzed variables (ethnic, deprivation score vaccination disparities and pre-existing conditions) that can affect the outcomes. The vaccine effectiveness among those ≥18 years of age (August 16, 2021 to March 27, 2022) was analyzed.

RESULTS Of the total cases (n= 22,072,550), hospitalizations (n=848,911) and deaths (n=175,070) due to COVID-19 in the UK; 51.3% of cases (n=11,315,793), 28.8% of hospitalizations (n=244,708), and 16.4% of deaths (n=28,659) occurred during the Omicron variant surge. When comparing the period of February 28 - May 1, 2022 with the prior 12-weeks, we observed a significant increase in the case fatality rate (0.19% vs 0.41%; RR 2.11 [2.06-2.16], p<0.001) and the risk of hospitalizations (1.58% vs 3.72%; RR 2.36[2.34-2.38]; p<0.001). During the same period, we also observed a significant increase in the proportion of cases (23.7% vs 40.3%; RR1.70 [1.70-1.71]; p<0.001) among ≥50 years of age and hospitalizations (39.3% vs 50.3%;RR1.28 [1.27-1.30]; p<0.001) and deaths (67.89% vs 80.07%;RR1.18 [1.16-1.20]; p<0.001) among ≥75 years of age. The vaccine effectiveness (VE) for the third dose was in negative since December 20, 2021, with a significantly increased proportion of SARS-CoV2 cases hospitalizations and deaths among the vaccinated; and a decreased proportion of cases, hospitalizations, and deaths among the unvaccinated. The pre-existing conditions were present in 95.6% of all COVID-19 deaths and we also observed various ethnic, deprivation score and vaccination rate disparities that can adversely affect hospitalization and deaths among the compared groups based on the vaccination status.

CONCLUSIONS There is no discernable optimal vaccine effectiveness among ≥18 years of age, vaccinated third dose population since December 20, 2021 during the beginning of the Omicron variant surge. Pre-existing conditions, ethnicity, deprivation score, and vaccination rate disparities data need to be adjusted by the development of validated models for evaluating VE for hospitalizations and deaths. The increased proportion of cases with significantly increased risk of hospitalizations and deaths among the elderly population during the Omicron variant surge underscores the need to prevent infections in the elderly irrespective of vaccination status with uniform screening protocols and protective measures.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Conflicts of interests: The authors have no conflict of interest or financial relationships relevant to the submitted review to disclose.
Authorship: This manuscript was initially drafted by the first author, and approved by all authors. VRE analyzed the data; VKP, DN, RR, KRM and ASN verified all the data and the submitted data was reviewed by all authors. All authors have access to the complete data that was analyzed for this manuscript.
Funding: None; The author(s) received no financial support for the research, authorship, and/or publication of this article
IRB approval: Not required.
We addressed the following in the current revision 1)We used NIMS data population as the denominator for comparing outcomes (SARS-CoV2 cases, hospitalizations, and deaths per 100,000 population) among various age groups based on vaccination status which was also published by UKHSA in their regular weekly vaccine surveillance reports in between August 16, 2021 to March 27, 2022. Our use of unvaccinated population of NIMS databases for the vaccine effectiveness may have overestimated unvaccinated population by ~8.4% to 9.0% and may have underestimated the vaccine effectiveness by about 7.5% to 12.5% which is not a major issue during the Omicron variant surge with waned vaccine effectiveness as outlined in the supplemental appendix through our comparative validation of both the database denominators. 2)We proposed suggestions for how the validation methods can be developed for evaluation of the vaccine effectiveness for the SARS-CoV2 hospitalizations and deaths.